-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31

Benzinga·11/20/2026 18:27:17
Listen to the news
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $33 to $31.